- Home
- RPID
as of 12-17-2025 3:34pm EST
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 178.6M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 101.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $4.50 | Next Earning Date: | 11-07-2025 |
| Revenue: | $30,523,000 | Revenue Growth: | 16.63% |
| Revenue Growth (this year): | 19.36% | Revenue Growth (next year): | 21.48% |
Compare RPID vs Leading Stocks
See how RPID stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RPID Rapid Micro Biosystems Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.